Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
Craig R. Lee, Jasmine A. Luzum, Katrin Sangkuhl, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 5, pp. 959-967
Open Access | Times Cited: 288

Showing 1-25 of 288 citing articles:

CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association
Naveen L. Pereira, Sharon Cresci, Dominick J. Angiolillo, et al.
Circulation (2024) Vol. 150, Iss. 6
Closed Access | Times Cited: 23
The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data
Yitian Zhou, Volker M. Lauschke
The Pharmacogenomics Journal (2022) Vol. 22, Iss. 5-6, pp. 284-293
Open Access | Times Cited: 67
Drug metabolism and drug transport of the 100 most prescribed oral drugs
Ditte B. Iversen, Nanna Elman Andersen, Ann‐Cathrine Dalgård Dunvald, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 131, Iss. 5, pp. 311-324
Open Access | Times Cited: 45
From pharmacogenetics to pharmaco-omics: Milestones and future directions
Chiara Auwerx, Marie C. Sadler, Alexandre Reymond, et al.
Human Genetics and Genomics Advances (2022) Vol. 3, Iss. 2, pp. 100100-100100
Open Access | Times Cited: 42
The STROMICS genome study: deep whole-genome sequencing and analysis of 10K Chinese patients with ischemic stroke reveal complex genetic and phenotypic interplay
Si Cheng, Zhe Xu, Shengzhe Bian, et al.
Cell Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 35
Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease
Nicholas R. Powell, Tiebing Liang, Joseph Ipe, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23
Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score
Cameron D. Thomas, Francesco Franchi, Joseph S. Rossi, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 15, pp. 1370-1381
Closed Access | Times Cited: 9
CYP2C19 Genotype‐Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure
Kayla R. Tunehag, Ashton F. Pearce, Layna P. Fox, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Risk of major adverse cardiovascular events in CYP2C19LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI: Meta‐analysis
Mohitosh Biswas, M Murad, Maliheh Ershadian, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 2
Open Access | Times Cited: 1
Precision Medicine in Interventional Cardiology: Implications for Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
Mattía Galli, Luis Ortega‐Paz, Francesco Franchi, et al.
Pharmacogenomics (2022) Vol. 23, Iss. 13, pp. 723-737
Closed Access | Times Cited: 34
Ethnic Diversity and Warfarin Pharmacogenomics
Innocent G. Asiimwe, Munir Pirmohamed
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 28
Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
Anh B. Nguyen, Larisa H. Cavallari, Joseph S. Rossi, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 28
Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study
Margarita-Ioanna Koufaki, Vasileios Fragoulakis, Xando Díaz-Villamarín, et al.
Human Genomics (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 19
Pharmacogenomics in Asians: Differences and similarities with other human populations
Mohitosh Biswas, Pimonpan Jinda, Chonlaphat Sukasem
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 1, pp. 27-41
Closed Access | Times Cited: 17
Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention
Seung Hun Lee, Young‐Hoon Jeong, David Hong, et al.
КАРДИОЛОГИЯ УЗБЕКИСТАНА (2023) Vol. 16, Iss. 7, pp. 829-843
Closed Access | Times Cited: 17
From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
Qamar Shubbar, Aminah Alchakee, Khaled Walid Issa, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Clinical impact of preemptive pharmacogenomic testing on antiplatelet therapy in a real-world setting
Amanda Massmann, Kurt D. Christensen, Joel Van Heukelom, et al.
European Journal of Human Genetics (2024) Vol. 32, Iss. 8, pp. 895-902
Closed Access | Times Cited: 7
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis
Mattía Galli, Giovanni Occhipinti, Stefano Benenati, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2024) Vol. 10, Iss. 6, pp. 526-536
Closed Access | Times Cited: 7
Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program
Christina L. Aquilante, Katy E. Trinkley, Yee Ming Lee, et al.
American Journal of Health-System Pharmacy (2024) Vol. 81, Iss. 12, pp. 555-562
Closed Access | Times Cited: 6
The association of CYP2C19LoF alleles with adverse clinical outcomes in stroke patients taking clopidogrel: An updated meta‐analysis
Mohitosh Biswas, Md. Shahadat Hossain, Tahsin Ahmed Rupok, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 4
Open Access | Times Cited: 6
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention
Dominick J. Angiolillo, Mattía Galli, Dimitrios Alexopoulos, et al.
КАРДИОЛОГИЯ УЗБЕКИСТАНА (2024) Vol. 17, Iss. 22, pp. 2639-2663
Closed Access | Times Cited: 6
Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians’ attitudes to sociocultural differences between patients across the globe
Justo Pinzón-Espinosa, Marte Z. van der Horst, Janneke Zinkstok, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 25
CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel
Emma Magavern, Benjamin Meir Jacobs, Helen R. Warren, et al.
JACC Advances (2023) Vol. 2, Iss. 7, pp. 100573-100573
Open Access | Times Cited: 16
Unlocking Genetic Profiles with a Programmable DNA‐Powered Decoding Circuit
Junlan Liu, Chao Zhang, Jinxing Song, et al.
Advanced Science (2023) Vol. 10, Iss. 20
Open Access | Times Cited: 14
Exploring the molecular mechanism of notoginsenoside R1 in sepsis-induced cardiomyopathy based on network pharmacology and experiments validation
Ruifei Shao, Wei Li, Rui Chen, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top